glp-1 obesity drug news today september 15 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo Alarming rise in weight loss

Potential risks include: Low blood sugar, especially if you also take other diabetes medications Gallbladder issues Mild to severe allergic reactions, including anaphylaxis in rare cases Possible muscle loss, if you lose weight too quickly (which is why balanced nutrition and movement matter) If youre pregnant or nursing, you should not take GLP-1s

They mimic the actions of the endogenous hormone GLP-1, released by the gut after eating

Its true appetite-suppressing power unlocks incrementally as the concentration of the medication builds safely in your bloodstream over successive weeks

Our obesity crisis has worsened in recent years, and most studies based on dietary changes alone or dietary changes with exercise demonstrate that patients achieve and sustain far less weight loss compared to patients who take GLP-1 angonists

Diabetes, weight loss and now heart health: A new family of drugs is changing the way scientists are thinking about obesity and more uses are on the horizon Support sound science and smart stories Help us make scientific knowledge accessible to all Donate today Few drugs have achieved the stardom that semaglutide, marketed in the United States as Ozempic or Wegovy, has today